Switch theme
Sign up to access all valuation multiples
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
2020
215
LTM Revenue n/a
LTM EBITDA -$74.2M
-$23.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Achilles Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$74.2M.
In the most recent fiscal year, Achilles Therapeutics achieved revenue of n/a and an EBITDA of -$70.5M.
Achilles Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Achilles Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$74.7M | -$70.5M | -$70.7M | -$74.2M | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | -Infinity% | XXX |
| Net Profit | -$61.1M | -$71.2M | -$69.7M | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 14, 2025, Achilles Therapeutics's stock price is $1.
Achilles Therapeutics has current market cap of $58.9M, and EV of -$23.5M.
See Achilles Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$23.5M | $58.9M | XXX | XXX | XXX | XXX | $-0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 14, 2025, Achilles Therapeutics has market cap of $58.9M and EV of -$23.5M.
Achilles Therapeutics's trades at n/a LTM EV/Revenue multiple, and 0.3x LTM EBITDA.
Analysts estimate Achilles Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Achilles Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$23.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.3x | XXX | XXX | XXX |
| P/E | -0.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAchilles Therapeutics's NTM/LTM revenue growth is n/a
Achilles Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Achilles Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Achilles Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Achilles Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Achilles Therapeutics acquired XXX companies to date.
Last acquisition by Achilles Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Achilles Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Achilles Therapeutics founded? | Achilles Therapeutics was founded in 2020. |
| Where is Achilles Therapeutics headquartered? | Achilles Therapeutics is headquartered in United States of America. |
| How many employees does Achilles Therapeutics have? | As of today, Achilles Therapeutics has 215 employees. |
| Who is the CEO of Achilles Therapeutics? | Achilles Therapeutics's CEO is Dr. Iraj Ali, PhD. |
| Is Achilles Therapeutics publicy listed? | Yes, Achilles Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Achilles Therapeutics? | Achilles Therapeutics trades under ACHL ticker. |
| When did Achilles Therapeutics go public? | Achilles Therapeutics went public in 2021. |
| Who are competitors of Achilles Therapeutics? | Similar companies to Achilles Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Achilles Therapeutics? | Achilles Therapeutics's current market cap is $58.9M |
| What is the current EBITDA of Achilles Therapeutics? | Achilles Therapeutics's last 12-month EBITDA is -$74.2M. |
| What is the current EV/EBITDA multiple of Achilles Therapeutics? | Current EBITDA multiple of Achilles Therapeutics is 0.3x. |
| Is Achilles Therapeutics profitable? | Yes, Achilles Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
